History of Malaria

The Hippocratic corpus described the recurring fevers now recognized as malaria as "tertian" (returning every third day) and "quartan" (every fourth day) fevers, and linked them to climate, season, and locality. Galen and later physicians elaborated these observations, but the dominant explanation for centuries was miasma — the idea that disease was caused by bad air, especially from marshes. The Italian word "malaria" itself comes from mal'aria, "bad air," and the Pontine Marshes south of Rome were a notorious zone of the disease. Malaria was also endemic in the Nile Delta, the Mediterranean, and other tropical and subtropical regions, where it shaped agriculture, settlement, and labor.

The most important treatment for malaria before the modern era was quinine, derived from the bark of Cinchona trees native to the Andes. Indigenous Andean peoples, including the Quechua, used the bark to treat fevers, although the details of precolonial use and European acquisition remain debated. Jesuit missionaries carried the bark from Peru to Europe by the 1640s. A later legend attributed its discovery to the cure of the Countess of Chinchón in 1647, but this story is probably apocryphal. In 1820, the French chemists Pelletier and Caventou isolated quinine from the bark, making it available as a standardized medicine. In the nineteenth century British and Dutch projects transferred cinchona plants and seeds from the Andes to plantations in India, Ceylon, and Java; high-yield seed collected for Charles Ledger helped Java dominate later production.

Quinine's effectiveness did not by itself settle debates about marshes, climate, or contagion; useful treatment and correct explanation did not arrive together. The drug's trade linked Indigenous Andean knowledge to European pharmacy, imperial botany, plantation production, and military medicine, and it remained the mainstay of malaria treatment for more than two centuries.

In 1880, the French army physician Alphonse Laveran observed parasites in the blood of a malaria patient in Bône, Algeria, establishing that the disease was caused by a protozoan. He received the 1907 Nobel Prize in Physiology or Medicine "in recognition of his work on the role played by protozoa in causing diseases."

In 1897, Ronald Ross observed a developing stage of the human malaria parasite in a dapple-winged anopheline mosquito at Secunderabad, India. He then used bird malaria to demonstrate more of the parasite's mosquito cycle and transmission. He received the 1902 Nobel Prize in Physiology or Medicine "for his work on malaria, by which he has shown how it enters the organism and thereby has laid the foundation for successful research on this disease and methods of combating it."

The Italian physician Giovanni Battista Grassi and his team demonstrated transmission of human malaria by Anopheles claviger in Italy in 1898–1899. The Ross–Grassi priority dispute — over who first established mosquito transmission — was a significant episode in the history of the disease, but the two lines of work together established the parasite–vector relationship.

Later work clarified stages that neither group had seen. In 1948, Henry Shortt and Cyril Garnham and their colleagues demonstrated the parasite's pre-erythrocytic development in the liver. Blood microscopy, mosquito experiments, and tissue studies together revealed a complex life cycle rather than a simple germ passing directly from person to person.

Vector theory turned drains, standing water, window screens, bed nets, housing, and insecticides into medical technologies. It also gave colonial authorities tools for protecting ports, plantations, mines, and European enclaves without necessarily improving living conditions for everyone. Malaria control could therefore combine genuine prevention with unequal priorities and coercive environmental schemes.

The discovery of the mosquito vector helped establish tropical medicine as a distinct discipline in the early twentieth century, with institutions such as the Liverpool School of Tropical Medicine (1898) and the London School of Tropical Medicine (1899), renamed the London School of Hygiene and Tropical Medicine in 1924. Malaria was a central concern of colonial medicine, and its control was often tied to the protection of European settlers and the economic interests of colonial powers.

After the Second World War, the widespread use of DDT and the development of synthetic antimalarials such as chloroquine encouraged a global eradication campaign. The World Health Organization's Global Malaria Eradication Programme, launched in 1955, achieved sharp reductions in some countries, but uneven infrastructure, war, migration, limited community participation, and the exclusion of much of sub-Saharan Africa prevented a universal result. The CDC's history of malaria traces the rise and limits of this campaign.

In 2015, the results of a large Phase III trial of the RTS,S/AS01 malaria vaccine (Mosquirix) were published, showing that it significantly reduced malaria and severe malaria in young children. In October 2021, the WHO recommended broad use of RTS,S/AS01 among children living in regions with moderate to high P. falciparum malaria transmission. In October 2023, WHO recommended a second safe and effective malaria vaccine, R21/Matrix-M. Vaccines are now being rolled out in routine childhood immunization programmes across Africa, and are expected to save tens of thousands of young lives every year.